No Data
No Data
CareDx Raised to Equal-Weight From Underweight by Wells Fargo
Wells Fargo Upgrades CareDx(CDNA.US) to Hold Rating, Cuts Target Price to $24
Craig-Hallum Maintains CareDx(CDNA.US) With Buy Rating, Announces Target Price $40
CareDx Analyst Ratings
H.C. Wainwright Maintains CareDx(CDNA.US) With Hold Rating, Announces Target Price $26
Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT), CareDx (CDNA) and Intellia Therapeutics (NTLA)